ALTANA AG has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted ALTANA Pharma marketing approval for Alvesco (Ciclesonide), a lung-activated inhaled corticosteroid with novel release and distribution properties.
Alvesco is indicated as prophylactic treatment of persistent asthma in adults.
The United Kingdom is serving as the Reference Member State for the European Mutual Recognition Procedure that will be initiated to gain marketing approval for Alvesco in participating countries. This approval of Alvesco in the UK is another major milestone for ALTANA Pharma. Other approvals will follow, so that patients in many countries can benefit from Alvesco.